Logo

PerkinElmer: Robert Friel, Prahlad Singh, Alexis Michas

Aug 21, 2019

After serving 12 years as CEO of PerkinElmer, Robert Friel will step down from that position as well as from his role as chairman of the board, effective Dec. 29, 2019. He will continue to serve as an advisor until March 1, 2020. The firm also announced that Prahlad Singh, current president and COO of PerkinElmer, will become CEO on Dec. 30, 2019, and he has been elected a director of the company, effective today. Prior to joining PerkinElmer in 2014, Singh was general manager of GE Healthcare's women's health business.

PerkinElmer also said that Alexis Michas, currently lead director, will serve as non-executive chairman of PerkinElmer's board, starting Dec. 30.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.